Statins as potential therapeutic agents in multiple sclerosis

被引：11

作者：

Stüve O. ^{[1
]}

Prod'homme T. ^{[1
]}

Youssef S. ^{[1
]}

Dunn S. ^{[1
]}

Neuhaus O. ^{[1
]}

Weber M. ^{[1
]}

Hartung H.-P. ^{[1
]}

Steinman L. ^{[1
]}

Zamvil S.S. ^{[1
]}

机构：

[1] Department of Neurology, Univ. of California, San Francisco, San Francisco, CA 94143-0114

来源：

Current Neurology and Neuroscience Reports | 2004年 / 4卷 / 3期

基金：

美国国家卫生研究院;

关键词：

Multiple Sclerosis; Simvastatin; Atorvastatin; Experimental Autoimmune Encephalomyelitis; Major Histocompatibility Complex Class;

D O I：

10.1007/s11910-004-0044-2

中图分类号：

学科分类号：

摘要：

3-Hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors (ie, statins) are oral cholesterol-lowering drugs. Statins are well tolerated and have an excellent safety record. These agents competitively inhibit HMG CoA reductase, which is the enzyme that catalyzes the conversion of HMG CoA to L-mevalonate. Although L-mevalonate is a key intermediate in cholesterol synthesis, several of its metabolites are involved in post-translational modification of specific proteins involved in cell proliferation and differentiation. Thus, independent of their cholesterol-reducing properties, statins have important pleiotropic biologic effects. Recent reports indicate that statins have anti-inflammatory and neuroprotective properties. Whether statins will be of clinical benefit for patients with multiple sclerosis and other neurodegenerative diseases of the central nervous system will only be known after they are evaluated in prospective randomized clinical trials. Copyright © 2004 by Current Science Inc.

引用

页码：237 / 244

页数：7

共 91 条

[61]

Muhlethaler-Mottet A., Otten L.A., Steimle V., Mach B., Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA, EMBO J., 16, pp. 2851-2860, (1997)

[62]

Kwak B., Mulhaupt F., Myit S., Mach F., Statins as a newly recognized type of immunomodulator, Nat. Med., 6, pp. 1399-1402, (2000)

[63]

Dustin M.L., Shaw A.S., Costimulation: Building an immunological synapse, Science, 283, pp. 649-650, (1999)

[64]

Grakoui A., Bromley S.K., Sumen C., Et al., The immunological synapse: A molecular machine controlling T cell activation, Science, 285, pp. 221-227, (1999)

[65]

Abbas A.K., Murphy K.M., Sher A., Functional diversity of helper T lymphocytes, Nature, 383, pp. 787-793, (1996)

[66]

Panitch H.S., Hirsch R.L., Haley A.S., Johnson K.P., Exacerbations of multiple sclerosis in patients treated with gamma interferon, Lancet, 1, pp. 893-895, (1987)

[67]

Windhagen A., Nicholson L.B., Weiner H.L., Et al., Role of Th1 and Th2 cells in neurologic disorders, Chem. Immunol., 63, pp. 171-186, (1996)

[68]

Khoury S.J., Hancock W.W., Weiner H.L., Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with down-regulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain, J. Exp. Med., 176, pp. 1355-1364, (1992)

[69]

Begolka W.S., Vanderlugt C.L., Rahbe S.M., Miller S.D., Differential expression of inflammatory cytokines parallels progression of central nervous system pathology in two clinically distinct models of multiple sclerosis, J. Immunol., 161, pp. 4437-4446, (1998)

[70]

Liu J.S., Zhao M.L., Brosnan C.F., Lee S.C., Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions, Am. J. Pathol., 158, pp. 2057-2066, (2001)

← 1 2 3 4 5 6 7 8 9 10 →